Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanfanercept - HanAll Biopharma

Next Previous
Drug Profile

Tanfanercept - HanAll Biopharma

Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HBM-9036; HL 036; HL-036337; HL-189 - HanAll Biopharma; TNF-alpha blocker - HanAll Biopharma

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanAll Biopharma
  • Developer Daewoong Pharmaceutical; HanAll Biopharma; Harbour BioMed; Unknown
  • Class Anti-inflammatories; Biobetters; Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry eyes
  • Preclinical Uveitis
  • No development reported Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 06 Mar 2025 HanAll Biopharma initiates enrolment in a phase III VELOS-4 trial for Dry eyes in China (Opthalmic) (NCT06400589)
  • 06 Mar 2025 HanAll Biopharma re-initiates the phase III VELOS-4 trial in Dry eyes in USA (Opthalmic) (NCT06400589)
  • 01 May 2024 HanAll Biopharma initiates a phase III VELOS-4 trial for Dry eyes in USA (Opthalmic), before May 2024 (NCT06400589)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top